Aldeyra Therapeutics, Inc. (ALDX) Form 10-Q — Aug 6, 2026
Aldeyra Therapeutics reported a Q2 2026 net loss of $5.45 million, down 44% from $9.77 million a year earlier, as research and development spending fell 59% to $3.5 million. For the first six months of 2026, the net loss was $8.9 million versus $19.7 million in the year-ago period. The company ended the quarter with $45.1 million in cash and no debt after repaying its $15.0 million Hercules Capital loan in full on April 1, 2026. Management projects current cash will fund projected operating expenses into the second half of 2028, though additional financing will be needed to complete all planned activities.
Key figures
- Total Debt
- 0
- Total Assets
- 47540559
- Cash Position
- 45089786
- Shares Outstanding
- 60326421
- Cash runway
- into the second half of 2028
- Atm shares sold
- 0
- Q2 2026 ga expense
- 2365993
- Options outstanding
- 9279218
- Q2 2025 rnd expense
- 8505229
- Q2 2026 rnd expense
- 3484514
- Hercules loan repaid
- 15000000
- Atm capacity jefferies
- 75000000
- Stock price june 30 2026
- 2.13
- Six month 2026 rnd expense
- 5894089
- Csbu liability settled post quarter
- 1200000
- Options weighted avg exercise price
- 4.41
- Deferred collaboration revenue abbvie
- 6000000
Price after filing
Close on the filing date to close N calendar days later (from $1.55). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.